CN111072742B - Novel crystal form of medicine for treating hepatitis C and composition thereof - Google Patents
Novel crystal form of medicine for treating hepatitis C and composition thereof Download PDFInfo
- Publication number
- CN111072742B CN111072742B CN201911333859.3A CN201911333859A CN111072742B CN 111072742 B CN111072742 B CN 111072742B CN 201911333859 A CN201911333859 A CN 201911333859A CN 111072742 B CN111072742 B CN 111072742B
- Authority
- CN
- China
- Prior art keywords
- compound
- crystal form
- weight
- degrees
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a new crystal form of a medicine for treating hepatitis C and a composition thereof. After the crystal form T is further prepared into a proper preparation, the variation coefficient of the postprandial Cmax of a subject can be obviously reduced, so that the safety and the effectiveness of a medicine are more reliably guaranteed.
Description
Technical Field
The invention relates to the field of biological medicines, in particular to a novel crystal form of a medicine for treating HCV and a composition thereof.
Background
Hepatitis C Virus (HCV) infection is a worldwide epidemic with more than 2 billion of chronically infected people worldwide, with a chronic infection rate of 15% in egypt, 4.8% in pakistan, 3.2% in china, and the top three worldwide locations. The clinical manifestations of hepatitis c virus infection are diverse, mild to inflammation, severe to cirrhosis, liver cancer. Chronic hepatitis c may also be associated with certain extrahepatic manifestations, including rheumatoid arthritis, keratoconjunctivitis sicca, lichen planus, glomerulonephritis, mixed cryoglobulinemia, B-cell lymphoma, and delayed porphyria cutanea dermalis, which may be the result of an abnormal immune response in the body. And when the hepatitis C cirrhosis is in the decompensation stage, various complications can occur, such as ascites abdominal infection, upper gastrointestinal hemorrhage, hepatic encephalopathy, hepatorenal syndrome, liver failure and the like.
Sofosbuvir, known as Sofosbuvir in English, is a breakthrough drug developed by Gilidd science corporation for treating chronic hepatitis C, is approved to be marketed in the United states by the U.S. food and drug administration in 12 months in 2013, and is approved to be marketed in the European Union in 1 month 2014. The sofosbuvir can be used alone or in a compound way (combined with Ledipasvir or Velpatasvir) to treat the whole genotype hepatitis C, and the cure rate is over 95 percent.
A highly variable drug is defined as the coefficient of variation CV (in AUC and C) within an individual drug max Calculated intra-individual coefficient of variation) ≧ 30%, the drug is defined as a Highly Variable Drug (HVD). If bioequivalence between the test and reference formulations occurs, the 90% Confidence Interval (CI) of the Geometric Mean Ratio (GMR) of the bioequivalence indicators (i.e., AUC and Cmax) for both formulations must fall within the 80% to 125% bioequivalence range. According to incomplete statistics, about 15% to 20% of the FDA-declared drugs belong to highly variable drugs. Even if the high-variability drugs are compared by a reference preparation, the risk of biological inequivalence exists, so the research on the biological equivalence of the high-variability drugs is a problem which is always puzzled by pharmaceutical researchers.
World Health Organization (WHO) Parafosbuvir tablets
The bioequivalence research guideline recommends performing bioequivalence test of the sofosbuvir tablets in postprandial state, the administration dosage is 400mg, the tested population is healthy subjects, the detected component is orthoform medicine, and the result shows that the C of the sofosbuvir tablets in the postprandial state max Shows high variation with a coefficient of variation as high as 54%.
Disclosure of Invention
In one aspect, the present invention provides a crystalline form T of compound I, said crystalline form T comprising characteristic peaks at the 2 θ angle in the powder X-ray diffraction pattern obtained using CuKa radiation: 5.0 ° ± 0.2 °, 7.2 ° ± 0.2 °, 9.7 ° ± 0.2 °, 10.0 ° ± 0.2 °, 10.3 ° ± 0.2 ° and 19.1 ° ± 0.2 °, wherein said compound I has the structure:
in some embodiments, the 2 θ angle of form T in a powder X-ray diffraction pattern obtained using CuKa radiation comprises characteristic peaks: 5.0 ° ± 0.2 °, 7.2 ° ± 0.2 °, 9.7 ° ± 0.2 °, 10.0 ° ± 0.2 °, 10.3 ° ± 0.2 °, 19.1 ° ± 0.2 °, 21.0 ° ± 0.2 ° and 25.2 ° ± 0.2 °.
In some embodiments, the 2 θ angle of form T in a powder X-ray diffraction pattern obtained using CuKa radiation comprises characteristic peaks: 5.0 degrees +/-0.2 degrees, 7.2 degrees +/-0.2 degrees, 9.7 degrees +/-0.2 degrees, 10.0 degrees +/-0.2 degrees, 10.3 degrees +/-0.2 degrees, 16.1 degrees +/-0.2 degrees, 16.9 degrees +/-0.2 degrees, 18.3 degrees +/-0.2 degrees, 19.1 degrees +/-0.2 degrees, 20.1 degrees +/-0.2 degrees, 20.6 degrees +/-0.2 degrees, 21.0 degrees +/-0.2 degrees, 23.2 degrees +/-0.2 degrees, 24.6 degrees +/-0.2 degrees and 25.2 degrees +/-0.2 degrees.
In some embodiments, the form T has an X-ray diffraction pattern as shown in figure 1 obtained using CuKa radiation.
In another aspect, the invention provides a preparation method of crystal form T: adding the compound I into a solvent selected from 4-methyl-2-pentanone, cyclohexanone or 2-butanone, heating to dissolve, keeping the temperature and stirring, slowly dripping a small amount of an anti-solvent, slowly cooling, stirring, then quickly dripping a large amount of the anti-solvent, further slowly cooling, stirring to crystallize, and filtering to obtain a white solid, namely a compound I crystal form T, wherein the anti-solvent is selected from one of ethyl acetate, butyl acetate or isopropyl acetate.
In some embodiments, the temperature of the warming dissolution is 45-55 ℃, preferably 45 ℃, 50 ℃ or 55 ℃.
In some embodiments, the first slow cooling is to a temperature of 20-25 ℃; preferably 20 ℃ or 25 ℃.
In some embodiments, the further slow cooling is to a temperature of 10-15 ℃; preferably 10 ℃ or 15 ℃.
In some embodiments, the speed of agitation is from 200 to 300 revolutions per minute; preferably 200 rpm, 250 rpm or 300 rpm.
In some embodiments, the volume of the small amount of anti-solvent is 20 to 40%, preferably 20%, 25%, 30%, 35% or 40% of the volume of solvent in which compound I is dissolved.
In some embodiments, the volume of the bulk anti-solvent is 3-5 times, preferably 3 times, 3.5 times, 4 times, 4.5 times, or 5 times the volume of the solvent in which compound I is dissolved.
In another aspect, the invention provides a pharmaceutical composition comprising compound I form T and a pharmaceutically acceptable excipient.
In some embodiments, the pharmaceutical composition contains compound I form T, mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.
In some embodiments, the pharmaceutical composition comprises, by weight, 20-40% of compound I form T, 20-40% mannitol, 20-40% microcrystalline cellulose, 2-8% croscarmellose sodium, 0.2-2% colloidal silicon dioxide, and 1-3% magnesium stearate.
In some embodiments, the pharmaceutical composition contains, by weight, 33.33% of compound I form T, 30.00% mannitol, 29.67% microcrystalline cellulose, 5.00% croscarmellose sodium, 0.50% colloidal silicon dioxide, and 1.50% magnesium stearate.
The novel crystal form T crystallization process recorded in the invention is simple and convenient, is easy for industrial production and has no hygroscopicity. After the crystal form T is further prepared into a proper preparation, the variation coefficient of the postprandial Cmax of a subject can be obviously reduced, so that the safety and effectiveness of a medicine are more reliably guaranteed.
Drawings
FIG. 1 is an X-ray diffraction pattern of compound I crystal form T by CuKa rays.
Detailed Description
Crystal form preparation example 1
Adding 4.0g of the compound I into 10ml of cyclohexanone solution, heating to 55 ℃ for dissolution, stirring at a heat preservation speed of 200r/min, slowly dropwise adding 2ml of ethyl acetate, slowly cooling to 20 ℃, stirring at a heat preservation speed of 2h, quickly adding 35ml of ethyl acetate, slowly cooling to 10 ℃, stirring at a heat preservation speed for crystallization for 2h, filtering, and drying the obtained filter cake in vacuum at 50 ℃ to obtain a white solid, namely a compound I crystal form T, wherein the total amount of the compound I crystal form T is 3.69g, and the purity is more than 99.5%. The crystalline form product was examined to have an X-ray diffraction pattern as shown in FIG. 1 obtained using CuKa radiation (X-ray powder diffraction patterns were collected on a D8Advance powder diffractometer using CuK alpha radiation (40kV, 40mA), a theta-theta goniometer, a 0.6mm diverging slit, a 2.5mm rope slit, a 0.02mm nickel plate, a one-dimensional array detector. The apparatus used certified corundum standards (SRM 1976 b) for performance checks.
Crystal form preparation example 2
Adding 4.0g of the compound I into 10ml of 2-butanone solution, heating to 45 ℃ for dissolution, keeping the temperature and stirring at the stirring speed of 300r/min, slowly dropwise adding 3ml of butyl acetate, slowly cooling to 25 ℃, keeping the temperature and stirring for 2h, then quickly adding 30ml of butyl acetate, slowly cooling to 15 ℃, keeping the temperature, stirring for crystallization for 2h, filtering, and carrying out vacuum drying on the obtained filter cake at 50 ℃ to obtain a white solid, namely a compound I crystal form T, wherein the total amount of the compound I crystal form T is 3.62g, and the purity is more than 99.5%. The spectrum of the sample was consistent with that of the sample obtained in preparation example 1 by X-ray powder diffraction analysis.
Crystal form preparation example 3
Adding 4.0g of the compound I into 10ml of 4-methyl-2-pentanone solution, heating to 50 ℃ for dissolving, keeping the temperature and stirring at the stirring speed of 250r/min, slowly dropwise adding 4ml of isopropyl acetate, then slowly cooling to 20 ℃, keeping the temperature and stirring for 2 hours, then quickly adding 40ml of isopropyl acetate, slowly cooling to 10 ℃, keeping the temperature and stirring for crystallization for 2 hours, filtering, and carrying out vacuum drying on the obtained filter cake at 50 ℃ to obtain a white solid, namely a compound I crystal form T, wherein the total amount of the compound I crystal form T is 3.74g, and the purity is more than 99.5%. The spectrum of the sample was consistent with that of the sample obtained in preparation example 1 by X-ray powder diffraction analysis.
Crystal form preparation example 4
Adding 4.0g of the compound I into 10ml of cyclohexanone solution, heating to 50 ℃ for dissolution, stirring at the heat preservation speed of 250r/min, slowly dropwise adding 3ml of isopropyl acetate, slowly cooling to 20 ℃, stirring at the heat preservation temperature for 2h, then quickly adding 50ml of isopropyl acetate, slowly cooling to 10 ℃, stirring at the heat preservation temperature for crystallization for 2h, filtering, and drying the obtained filter cake in vacuum at 50 ℃ to obtain a white solid, namely a compound I crystal form T, wherein the total amount is 3.66g, and the purity is more than 99.5%. The pattern was consistent with that of the sample obtained in preparation example 1 by X-ray powder diffraction analysis.
Crystal form preparation example 5
Adding 4.0g of the compound I into 10ml of cyclohexanone solution, heating to 50 ℃ for dissolving, keeping the temperature and stirring at a stirring speed of 250r/min, slowly dropwise adding 4ml of isopropyl acetate, slowly cooling to 20 ℃, keeping the temperature and stirring for 2h, then quickly adding 45ml of ethyl acetate, slowly cooling to 10 ℃, keeping the temperature and stirring for crystallization for 2h, filtering, and drying the obtained filter cake in vacuum at 50 ℃ to obtain a white solid, namely a compound I crystal form T, wherein the total amount of the compound I crystal form T is 3.79g, and the purity is more than 99.5%. The pattern was consistent with that of the sample obtained in preparation example 1 by X-ray powder diffraction analysis.
Crystal form preparation example 6
Adding 4.0g of the compound I into 10ml of cyclohexanone solution, heating to 55 ℃ for dissolving, keeping the temperature and stirring at a stirring speed of 200r/min, slowly dropwise adding 40ml of ethyl acetate, slowly cooling to 25 ℃, keeping the temperature and stirring for crystallization, filtering, and performing vacuum drying on the obtained filter cake at 50 ℃ to obtain a white solid, wherein the XRPD spectrum of the product has a larger difference with the XRPD spectrum of the crystal form T through detection.
Crystal form preparation example 7
Adding 4.0g of the compound I into 10ml of 4-methyl-2-pentanone solution, heating to 55 ℃ for dissolving, keeping the temperature and stirring at the stirring speed of 250r/min, slowly dropwise adding 35ml of isopropyl acetate, slowly cooling to 10 ℃, keeping the temperature and stirring for crystallization and crystallization, filtering, and carrying out vacuum drying on the obtained filter cake at 50 ℃ to obtain a white solid, wherein the XRPD spectrum of the product has a larger difference with that of the crystal form T through detection.
Crystal form preparation example 8
Adding 4.0g of the compound I into 10ml of acetone solution, heating to 50 ℃ for dissolution, stirring at the heat preservation speed of 250r/min, slowly dropwise adding 4ml of ethyl acetate, slowly cooling to 20 ℃, stirring at the heat preservation temperature for 2h, then quickly adding 40ml of ethyl acetate, slowly cooling to 10 ℃, stirring at the heat preservation temperature for crystallization for 2h, filtering, and performing vacuum drying on the obtained filter cake at 50 ℃ to obtain a white solid, wherein the XRPD spectrum of the product has a larger difference with that of the crystal form T through detection.
Study on hygroscopicity
Hygroscopicity of form T, form I and form VI was investigated as follows. Wherein the crystal form I and the crystal form VI are prepared by the method described in the patent with the publication number of CN 104039319B.
Taking a dry glass weighing bottle with a plug (the outer diameter is 50mm, the height is 15 mm), placing the glass weighing bottle in an artificial climate box (the set temperature is 25 +/-1 ℃, the relative humidity is 80 +/-2%) one day before the test, precisely weighing the glass weighing bottle, and recording the weight as m 1 . Taking a proper amount of the test sample, flatly paving the test sample in the weighing bottle, wherein the thickness of the test sample is about 1mm, accurately weighing the test sample, and recording the weight as m 2 . The weighing bottle is opened and is placed under the constant temperature and humidity condition for 24 hours together with the bottle cap. The cover of the weighing bottle is closed, the weighing bottle is precisely weighed, and the weight is recorded as m 3 . Percentage weight gain (M) = (M) 3 -m 2 )/(m 2 -m 1 )×100％。
Preparation example 1
Mixing: 40kg of compound I crystal form T, 36kg of mannitol, 29.6kg of microcrystalline cellulose, 3kg of croscarmellose sodium and 0.54kg of colloidal silicon dioxide are added into a mixing hopper, the mixing speed is set to be 10r/min, and the mixing time is 30min.
And (4) sieving I: after the mixing is finished, the mixture is sieved by a crushing and sizing machine, the aperture of a screen mesh is 2.0mm, and the rotating speed of the sizing machine is 500r/min.
And (5) sieving II: 0.06kg of colloidal silicon dioxide and 6kg of microcrystalline cellulose are sequentially added into a hopper of a crushing and sizing machine and sieved, the aperture of a screen mesh is 2.0mm, and the rotating speed of the sizing machine is 500r/min.
Premixing: and (3) adding the pretreated internal material mixture (namely the product obtained by sieving II) and 0.9kg of magnesium stearate into a mixing hopper, setting the mixing rotation speed at 10r/min, and mixing for 10min.
And (3) dry granulation: and adding the premixed mixture into a dry granulating machine for granulating, wherein the granulating parameters comprise feeding speed (8-12) r/min, extrusion speed (8-12) r/min, granulating speed (95-125) r/min, extrusion pressure (8-12) kN, side sealing pressure (10-20) kN and mesh number of a screen mesh is 24.
Total mixing: and adding the dry granulated material, the pretreated additional auxiliary material, 3kg of crosslinked carboxymethyl cellulose and 0.9kg of magnesium stearate into a mixing hopper, setting the mixing speed to be 10r/min, and mixing for 15min.
Sampling and detecting the content and the moisture of the intermediate product after the total mixing is finished, wherein the qualified standard is as follows: the content is 31.7-34.9%, and the water content is less than or equal to 4.0%.
Tabletting: the standard tablet weight was calculated from the intermediate content determination. The tabletting mould is a special-shaped punch, the filling depth, the pre-pressing thickness and the main tabletting thickness are adjusted, so that the pre-pressing pressure is less than or equal to 7.0KN, the host machine pressure is (13.0-24.0) kN, the production speed is (45 +/-5) kT/h, and the appearance, the average tablet weight, the tablet weight difference, the hardness and the disintegration time limit are controlled to meet the requirements in the process.
The plain sheet has the advantages of consistent sheet shape, complete and smooth surface, regular edge, uniform color and luster, and no phenomena of color change, color spots or pockmarks and the like; the difference of the tablet weight is controlled to be +/-3.5 percent, and the weight of each tablet is within the tablet weight control range; the hardness control range is 200N-300N; the disintegration time limit controls the total disintegration of the tablets in water within 15min.
Coating: preparing a film coating solution (stomach-soluble Opadry) with the concentration of 15% (w/w), and using the solution after swelling and dispersing for 1 h.
Starting up the machine for preheating, controlling the rotating speed of the main machine within the range of 1.6 r/min-5.0 r/min and the negative pressure within the range of 40 Pa-100 Pa, adjusting the temperature of a hot air cabinet to enable the inlet temperature to reach 55-80 ℃, adding the tabletting intermediate product into a coating pot, preheating the tablet core and automatically removing powder, and starting coating operation after the temperature of the tablet core is qualified.
The coating operation is started, the rotating speed of the main machine is controlled to be 1.6 r/min-11.0 r/min, the flow of the peristaltic pump is controlled to be 300 ml/min-800 ml/min, the atomization pressure is 0.45 MPa-0.50 MPa, the temperature of a tablet bed is 37-43 ℃, and the negative pressure is 40 Pa-100 Pa. The appearance was checked at any time during the coating process.
And when the liquid spraying is finished, controlling the rotating speed of the main machine to be 1.6 r/min-5.0 r/min, drying for 10min, stopping blowing hot air, and stopping the machine when the temperature is reduced to the room temperature to discharge the sheets.
The coating intermediate product has uniform appearance and color, smooth surface, no adhesion, no coating liquid falling off and the like, and the coating weight is controlled to be 2.0-4.0%. The final product contained 400mg of compound I per tablet.
Preparation example 2
The preparation method which is the same as the preparation example 1 is adopted to respectively prepare the preparation of which the main medicine is the compound I crystal form 1, and the dosage of each auxiliary material is the same as the preparation example 1. Wherein the crystal form 1 is prepared by a method described in a patent with a publication number of CN 104039319B.
Preparation example 3
The preparation method which is the same as the preparation example 1 is adopted to respectively prepare the preparation of which the main medicine is the compound I crystal form 6, and the dosage of each auxiliary material is the same as the preparation example 1. Wherein the crystalline form 6 is prepared by a method described in the patent publication No. CN 104039319B.
Determination of the coefficient of variation of the Crystal forms of different Compounds I
45 healthy subjects were randomly divided into 3 groups (n = 15), and each group of subjects took 1 tablet (each tablet containing 400mg of compound I) prepared in formulation preparation examples 1-3, respectively, in a postprandial state. Before the administration, a venous indwelling needle is placed on the forearm of a subject, about 0.5mL of blood needs to be discarded before blood sampling is carried out, then the blood sampling is carried out again, and a tube is sealed by using a proper amount of heparin sodium solution.
The blood sampling time points of the subjects were: venous blood was collected at 20 blood collection points, 0h before dosing (within 1h before dosing, before eating) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48h and 72h after dosing for 3mL per cycle.
Taking venous blood and determining the content of compound I in the plasma to obtain C max Values were calculated and coefficient of variation, CV, was calculated for each group and the results are given in the table below.
| Group of | C max Coefficient of variation CV |
| Preparation example 1 | 24.6％ |
| Preparation example 2 | 56.4％ |
| Preparation example 3 | 55.9％ |
The experimental results show that the subjects take the tablets prepared in preparation example 1 (i.e. compound I crystal form T is used as the raw material drug) for the postprandial administration of C max The coefficient of variation CV of (a) is only 24.6%, less than 30%. And the tablet prepared by adopting the compound crystal form I or the compound crystal form VI is used for the postprandial treatment of the subjects max The coefficient of variation CV of (A) is higher than 50%, and the experimental result and the tested subject take FDA marketed drugs
The results obtained were consistent.
Claims (5)
1. A pharmaceutical composition comprising compound 1 form T and pharmaceutically acceptable excipients, said form T comprising characteristic peaks at the 2 Θ angle in a powder X-ray diffraction pattern obtained using CuKa radiation: 5.0 ° ± 0.2 °, 7.2 ° ± 0.2 °, 9.7 ° ± 0.2 °, 10.0 ° ± 0.2 °, 10.3 ° ± 0.2 °, 16.1 ° ± 0.2 °, 16.9 ° ± 0.2 °, 18.3 ° ± 0.2 °, 19.1 ° ± 0.2 °, 20.1 ° ± 0.2 °, 20.6 ° ± 0.2 °, 21.0 ° ± 0.2 °, 23.2 ° ± 0.2 °, 24.6 ° ± 0.2 ° and 25.2 ° ± 0.2 °, each 2 θ value has an error of ± 0.2 degrees (2 θ), wherein compound 1 has a structure of:
2. the pharmaceutical composition of claim 1, wherein the form T has a diffraction pattern obtained using CuKa radiation as shown in figure 1.
3. A pharmaceutical composition according to any one of claims 1-2, comprising compound I form T, mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate.
4. The pharmaceutical composition according to any one of claims 1-2, comprising 20-40% by weight of compound I form T, 20-40% by weight of mannitol, 20-40% by weight of microcrystalline cellulose, 2-8% by weight of croscarmellose sodium, 0.2-2% by weight of colloidal silicon dioxide and 1-3% by weight of magnesium stearate.
5. The pharmaceutical composition according to any one of claims 1-2, comprising 33.33% by weight of compound I form T, 30% by weight of mannitol, 29.67% by weight of microcrystalline cellulose, 5% by weight of croscarmellose sodium, 0.5% by weight of colloidal silicon dioxide and 1.5% by weight of magnesium stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911333859.3A CN111072742B (en) | 2019-12-23 | 2019-12-23 | Novel crystal form of medicine for treating hepatitis C and composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911333859.3A CN111072742B (en) | 2019-12-23 | 2019-12-23 | Novel crystal form of medicine for treating hepatitis C and composition thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111072742A CN111072742A (en) | 2020-04-28 |
| CN111072742B true CN111072742B (en) | 2022-12-02 |
Family
ID=70316805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911333859.3A Active CN111072742B (en) | 2019-12-23 | 2019-12-23 | Novel crystal form of medicine for treating hepatitis C and composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111072742B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102858790A (en) * | 2010-03-31 | 2013-01-02 | 吉利德制药有限责任公司 | Nucleoside Phosphoramidates |
| CN104039319A (en) * | 2011-11-29 | 2014-09-10 | 吉利德法莫赛特有限责任公司 | Compositions and methods for treating hepatitis c virus |
| WO2016008461A1 (en) * | 2014-07-17 | 2016-01-21 | Zentiva, K.S. | A new form of sofosbuvir and a method of its preparation |
-
2019
- 2019-12-23 CN CN201911333859.3A patent/CN111072742B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102858790A (en) * | 2010-03-31 | 2013-01-02 | 吉利德制药有限责任公司 | Nucleoside Phosphoramidates |
| CN104039319A (en) * | 2011-11-29 | 2014-09-10 | 吉利德法莫赛特有限责任公司 | Compositions and methods for treating hepatitis c virus |
| WO2016008461A1 (en) * | 2014-07-17 | 2016-01-21 | Zentiva, K.S. | A new form of sofosbuvir and a method of its preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111072742A (en) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110054624B (en) | Berberine hydrochloride and caffeic acid eutectic compound, preparation method, composition and application thereof | |
| CN110981910B (en) | Novel crystal form without hygroscopicity and low variability for treating hepatitis C | |
| CN105121434B (en) | Canagliflozin monohydrate and its crystal formation, their preparation method and purposes | |
| CN110041326B (en) | Eutectic compound of berberine hydrochloride and fumaric acid, preparation method, composition and application thereof | |
| CN105193752A (en) | Vildagliptin tablet and preparation method thereof | |
| CN106667936B (en) | Sofosbuvir tablet and preparation method thereof | |
| CN109988104B (en) | Kaempferol and isonicotinamide eutectic crystal, preparation method, pharmaceutical composition and application thereof | |
| CN113651770B (en) | Epalrestat crystal form, and preparation method and application thereof | |
| CN111072742B (en) | Novel crystal form of medicine for treating hepatitis C and composition thereof | |
| EP3653603A1 (en) | Fenlean (flz) crystal g form, preparation method, and composition and use thereof | |
| CN107522625A (en) | A kind of dezocine A crystal formations and preparation method thereof | |
| CN106924237B (en) | It is a kind of containing En Gelie is net and the pharmaceutical composition of Metformin hydrochloride | |
| WO2021203409A1 (en) | Novel non-hygroscopic low-variability crystalline form for treatment of hepatitis c | |
| EP3653601A1 (en) | Fenlean (flz) crystal b form, preparation method, and composition and use thereof | |
| CN103709156B (en) | A kind of Dasatinib polycrystalline form medicament and preparation method thereof | |
| CN110256300B (en) | Metformin hydrochloride compound and metformin hydrochloride tablet composition | |
| CN107519144A (en) | A kind of preparation method of telmisartan amlodipine tablets | |
| CN104873471A (en) | Rabeprazole sodium tablet and rabeprazole sodium enteric-coated tablet | |
| CN112294768A (en) | Ezetimibe tablets and method for improving dissolution rate thereof | |
| CN111662355B (en) | Mifepristone crystal W-type solid matter, preparation method, pharmaceutical composition and application thereof | |
| CN113943282B (en) | Pioglitazone hydrochloride para-aminosalicylic acid eutectic crystal, preparation method, composition and application thereof | |
| CN111233956B (en) | Crystal form of sofosbuvir and preparation method thereof | |
| CN113214066B (en) | Gossypol crystal II substance, preparation method, composition and application thereof | |
| WO2022166369A1 (en) | Crystal form of compound, and preparation method therefor and use thereof | |
| CN109988216B (en) | Betulin crystal D-type substance, preparation method, composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |